伊曲康唑：关于药物相互作用和生物利用度的注意事项。
Itraconazole: Precautions regarding drug interactions and bioavailability.
作者信息
Puttick M P, Phillips P
机构信息
Department of Medicine, St Paul's Hospital, and Division of Infectious Diseases, University of British Columbia, Vancouver, British Columbia.
出版信息
Can J Infect Dis. 1994 Jul;5(4):179-83. doi: 10.1155/1994/612027.
OBJECTIVE
To describe patients with fungal infections in whom drug interactions and bioavailability problems were associated with itraconazole treatment failure.
DESIGN
Retrospective chart review.
SETTING
Two tertiary care university-affiliated teaching hospitals.
POPULATION STUDIED
Itraconazole-treated patients between 1990 and 1992.
MAIN RESULTS
Four patients treated with itraconazole were identified in whom suboptimal serum itraconazole levels were associated with relapse of disseminated histoplasmosis, treatment failure of invasive aspergillosis or development of superficial mycoses. Low serum itraconazole levels were associated with concurrent therapy with rifampin or agents inhibiting gastric acid secretion, with administration of itraconazole capsule contents through a nasogastric tube or with the presence of aids.
CONCLUSIONS
It is recommended that serum itraconazole levels be measured in patients with potentially life-threatening mycoses if coexistent factors may interfere with itraconazole therapy.
目的
描述那些因药物相互作用和生物利用度问题导致伊曲康唑治疗失败的真菌感染患者。
设计
回顾性病历审查。
地点
两家大学附属三级护理教学医院。
研究对象
1990年至1992年间接受伊曲康唑治疗的患者。
主要结果
确定了4例接受伊曲康唑治疗的患者，其血清伊曲康唑水平不理想与播散性组织胞浆菌病复发、侵袭性曲霉病治疗失败或浅表真菌病的发生有关。血清伊曲康唑水平低与同时使用利福平或抑制胃酸分泌的药物、通过鼻胃管给予伊曲康唑胶囊内容物或患有艾滋病有关。
结论
如果存在可能干扰伊曲康唑治疗的共存因素，建议对患有潜在危及生命的真菌病的患者检测血清伊曲康唑水平。
Zotero 插件